Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 18 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-Refractory Patients With Non-Muscle Invasive Bladder Cancer				Phase III, Phase II				HIS-0611-0602 NCT00406068
	Study to Investigate the Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients With Bladder Cancer Undergoing Radical or Total Cystectomy				Phase III				12002 NCT00306150
	Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer				Phase III				SWOG-S0337 S0337, NCT00445601
	Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer				Phase II, Phase I				RTOG-0524 NCT00238420
	Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer				Phase II, Phase I				WBPDT-577-04 NCT00322699
	Phase I & II Trial of Intravesicular Abraxane for Treatment-Refractory Bladder Cancer				Phase II, Phase I				AAAC1114 NCT00583349
	Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin				Phase II				SWOG-S0353 S0353, NCT00234039
	Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor				Phase II				CINJ-3330 NCT00161187
	Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer				Phase II				BC-07-01.CTIL NCT00595088
	Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer				Phase II				WCCC-UWI06-8-01 UWI06-8-01, CO06810, H2007-0250, 07-1270-03, NCT00666562


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute